Progress in Xenotransplantation: Immunologic Barriers, Advances in Gene Editing, and Successful Tolerance Induction Strategies in Pig-To-Primate Transplantation

Daniel L. Eisenson¹,², Yu Hisadome¹ and Kazuhiko Yamada¹,³*

¹ Columbia Center for Translational Immunology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, United States, ² Department of Surgery, The Johns Hopkins Hospital, Baltimore, MD, United States, ³ Department of Surgery, Columbia University Irving Medical Center, New York, NY, United States

Organ transplantation is the most effective treatment for end stage organ failure, but there are not enough organs to meet burgeoning demand. One potential solution to this organ shortage is xenotransplantation using pig tissues. Decades of progress in xenotransplantation, accelerated by the development of rapid genome editing tools, particularly the advent of CRISPR-Cas9 gene editing technologies, have enabled remarkable advances in kidney and heart xenotransplantation in pig-to-nonhuman primates. These breakthroughs in large animal preclinical models laid the foundation for three recent pig-to-human transplants by three different groups: two kidney xenografts in brain dead recipients deemed ineligible for transplant, and one heart xenograft in the first clinical grade study of pig-to-human transplantation. However, despite tremendous progress, recent data including the first clinical case suggest that gene-modification alone will not overcome all xenogeneic immunologic barriers, and thus an active and innovative immunologic strategy is required for successful xenotransplantation. This review highlights xenogeneic immunologic barriers, advances in gene editing, and tolerance-inducing strategies in pig-to-human xenotransplantation.

Keywords: xenotransplantation, thymic transplantation, Mixed hematopoietic cell chimerism, thymokidney, vascularized thymic lobe transplantation

Abbreviations: β4GALNT2, β-1,4-N-acetyl-galactosaminytransferase 2; CD40L, CD40 ligand; CMAH, cytidine-monophosphate-N-acetyl-neuraminic acid hydroxylase; EC, endothelial cell; EPCR, endothelial protein receptor; GalTKO, α-1,3 Galactosyl transferase gene knockout; hCD47, human CD47; HO, heme-oxygenase; HSCTx. Hematopoietic stem cell transplantation; hTBM, human thrombomodulin; IBRMTx, intra-bone marrow transplantation; MHC, major histocompatibility complex; mAb, monoclonal antibody; Nab, natural antibody; NH, not human primate; NK, natural killer; NYU, New York University; PBMC, Peripheral blood mononuclear cells; POD, post operative day; SIRPα, Signal-regulatory protein alpha; SLA, swine leukocyte antigen; SMPDL-3b, Sphingomyelin phosphodiesterase acid-like 3b; Tg, Transgenic; TSP-1, thrombospondin-1; UAB, University of Alabama; UMMC, University of Maryland Medical Center; XTx, Xenotransplantation; VTL, Vascularized thymic lobe transplantation.
INTRODUCTION

Almost seventy years after the first successful kidney transplant by Joseph Murray in 1954 (1), transplantation has become standard of care for end organ failure. Murray’s transplant was termed homotransplantation, as it occurred between genetically identical twins; success in allotransplantation, or transplant between genetically different humans, required advances in immunosuppression that soon came with azathioprine and later cyclosporine (2, 3). As a result of this success, one of the central problems in the field of transplantation is that there are simply not enough organs to meet demand. Xenotransplantation, or transplant across species barriers, has long been proposed to solve this organ shortage, but interspecies immunologic barriers proved difficult to overcome (4–7).

Early xenotransplantation efforts utilized nonhuman primates (NHPs) as donors and achieved some notable successes. In 1963–1964, Keith Reemtsma at Tulane University in Louisiana transplanted chimpanzee kidneys into six patients with end stage renal failure (without long-term dialysis options), utilizing immunosuppression of azathioprine, actinomycin C, and steroids. While most recipients rejected organs within eight weeks of transplant, one patient survived for nine months (8). Due to ethical concerns about the use of primates in terminal procedures as well as practical issues of organ availability, the xenotransplantation community shifted from primates to pigs as donors (9–11). Pigs are more widely available, but present greater immunologic barriers: much of xenotransplantation research for the last thirty years has been devoted to understanding the immunologic obstacles in pig-to-primate transplantation and to modifying both donor pigs as well as recipient NHP immunologic responses.

In addition to immunologic barriers limiting organ survival in pig-to-primate transplantation, concerns about the transmission of zoonotic infections tempered early enthusiasm for xenotransplantation. These concerns were heightened with the 1997 discovery of porcine endogenous retroviruses (PERVs) that could infect human epithelial cells in vitro (12), and catalyzed additional research in PERVs — some groups have used genome editing to inactivate PERVs in pigs used for xenotransplantation (13) — as well as the development of diagnostic tools to assess for other pig-derived pathogens, including porcine cytomegalovirus (PCMV) (14). While comprehensive discussion of zoonosis is outside the scope of this review, pre-clinical and early clinical data suggest that zoonotic infection from swine will likely be rare — there has been no evidence for infections of humans or nonhuman primates caused by pig xenotransplantation products (14).

Decades of progress in xenotransplantation, accelerated by the development of rapid genome editing technology, particularly the advent of CRISPR-Cas9 technologies (15, 16), have enabled remarkable advances in pig-to-NHP transplantation: >6 months survival in life-supporting pig-to-baboon kidney transplants (17, 18), >6 months survival of heterotopic and orthotopic pig-to-baboon heart models (19–21), and, more recently >1 year survival in life-supporting pig-to-macaque kidney transplants (22). These breakthroughs in large animal preclinical models laid the foundation for clinical experiments in the United States. Over the last six months, three institutions have transitioned from preclinical studies using NHP recipients to preclinical studies (and one clinical study) using human recipients. Each of these approaches was different. New York University (NYU) and the University of Alabama (UAB) implanted kidneys into brain dead patients (deemed ineligible for organ donation) for a short period of time (less than 74 hours). The NYU team used kidneys from pigs that were genetically engineered to remove α,1,3-galactosyltransferase, called Gal “knock out” (GalTKO) pigs, while the UAB team used kidneys from pigs that were the product of more extensive gene editing: four genes “knocked out” (including α,1,3-galactosyltransferase, and pig growth hormone receptor), and multiple human genes (including genes encoding complement regulatory proteins and other proteins involved in normal human anti-coagulation) added. The University of Maryland Medical Center (UMMC) identified a patient with heart failure in the absence of liver or kidney failure who was not a candidate for implanted mechanical circulatory support or allotransplant and obtained FDA approval for compassionate use of a xenograft. They used the same genetically modified pigs as those used in the UAB study.

These recent experiments confirmed encouraging results from NHP studies and have led to a resurgence of enthusiasm for xenotransplantation. However, the UMMC clinical case also suggests that additional strategies will be required for long-term success of clinical xenotransplantation. Gene-modification alone cannot overcome all xenogeneic immunologic barriers, and an active and innovative immunologic strategy will be required for successful xenotransplantation. Considering these developments and the imminent future of clinical xenotransplantation, this article provides a brief overview of immunologic barriers in pig-to-human xenotransplantation, highlights progress achieved through gene editing technologies, and outlines a way forward through tolerance-inducing strategies.

IMMUNOLOGICAL BARRIERS IN PIG-TO-PRIMATE XENOTRANSPLANTATION

Transplanted organs across species barriers elicit more robust immune responses than are seen in allotransplantation. The innate immune system plays a more active role in rejection of xenografts than it does in rejection of allografts for reasons that we will detail, but both the innate and adaptive immune systems participate in these responses.

A. Innate Immune Barriers to Xenotransplantation

The key components of the innate immune system that are involved in rejection of xenografts are natural antibodies, complement systems, and macrophages/natural killer cells. Natural antibodies (Nabs) directed against carbohydrate antigens on pig cells presented one of the first and most important obstacles to pig-to-primate xenotransplantation. These preformed antibodies — categorized as innate immunity because they are present without specific exposure to pig cells — led to hyperacute rejection within hours of transplantation. Gallili et al. discovered and isolated one important subset of these antibodies...
that is directed against a carbohydrate component (α-1,3-galactose, or “α-gal”) of a cell surface glycoprotein produced by an enzyme (α-1,3-galactosyltransferase) that is not functional in humans or old-world primates (23). Discovery of anti-gal antibodies in humans that recognize α-1,3-galactose residues on pig cells precipitated a decades-long effort to produce pigs without α-1,3-galactosyltransferase (24–27). Two additional targets of Nabs, NeuGc, a glycoprotein produced by cytidine-monophosphate-N-acetyl-neuraminic acid hydroxylase (CMAH) which is inactive in humans (28), and SDa, a blood group antigen produced by porcine β-1,4-N-acetyl-galactosaminyltransferase 2 (β4GALNT2), have also been identified (29). Together, antibodies to these three carbohydrate antigens make up more than 95% of preformed antibodies against pig cells (30, 31).

Incompatibilities between pig and primate complement systems were also recognized to be a significant barrier to pig-to-primate xenotransplantation. Complement proteins, activated by Nab-binding (classical pathway) or spontaneous binding (alternative pathway), have also been shown to lead to vascular injury and rejection, as porcine complement regulatory proteins do not effectively inhibit human complement activation (32). Accordingly, pigs expressing human complement regulatory proteins were some of the first transgenic pigs made for the purpose of xenotransplantation (33).

Macrophages and natural killer cells, too, have been shown to play important roles in rejection of pig-to-primate xenografts. Both cell types are present in rejecting xenografts, and studies suggest that these cells may generate potent anti-graft responses independent of T-cell activity (34, 35). Macrophages participate in rejection of grafts both indirectly, as mediators of inflammation, and directly, phagocytosing cells. Phagocytosis of xenogeneic cells has been the subject of particular study: signal regulatory protein (SIRP)α, an inhibitory receptor on macrophages that binds to CD47 on human cells to prevent phagocytosis, does not respond to porcine CD47 (36). As will be discussed later in this review, the discovery of inhibitory signaling species incompatibilities between pigs and primates has made human CD47 (hCD47) a candidate transgene for further genetic modifications of pig used in xenotransplantation.

B. Adaptive Immune Barriers to Xenotransplantation

As detailed above, the innate immune system presents formidable species-specific barriers to xenotransplantation that are not seen in human-to-human transplantation. In allotransplantation, the innate immune system plays a minor role, but the adaptive immune responses are primarily responsible for rejection of grafts. This disconnect led many to hypothesize that the innate immune system was the critical barrier to xenotransplantation and that adaptive responses were less important.

It was initially believed that differences between pig and primate MHC proteins would inhibit effective MHC-binding and adaptive immune responses across species barriers. Early studies in a pig-to-mouse transplant model seemed to confirm this theory, suggesting that xenogeneic adaptive immune responses were weaker than allogeneic immune responses (37); however, this was later found to be a function of decreased costimulatory signaling between mice and pigs, and not related to TCR-MHC binding (38). Indeed, subsequent studies have shown that human T cells are directly activated by antigens exposed by porcine SLA molecules, that they respond to xenomHC antigens at least as well as they do to allo-MHC antigens (39) *in vitro*, and that costimulatory interactions between porcine MHC and human MHC molecules are not limited by species incompatibilities as in a pig-to-mouse transplant models (40) *in vivo*.

In addition to direct human TCR and pig SLA interactions, human B and T cells are activated indirectly via presentation of pig antigens on human antigen presenting cells (41). In this way, B cells presenting pig antigens are induced by cognate T cells to produce anti-non gal antibodies (42). These antibodies precipitate antibody-mediated rejection, which, as in humans, is difficult to control with immunosuppressive medications. Given the large proportion of pig proteins that are slightly different from their functional equivalents in humans, there are countless other possible xenoantigens that may trigger adaptive induced antibody production. While the innate immune system presents an early barrier to survival of pig-to-human xenografts, overcoming adaptive immune responses – in particular, induced antibody production – will be essential for long-term survival of pig xenografts.

**GENETIC ENGINEERING FOR PIG-TO-PRIMATE XENOTRANSPLANTATION**

As discussed earlier, hyperacute rejection in early pig-to-primate transplants – due, in large part, to pre-formed Nabs – limited enthusiasm for the use of pigs as organ donors. Isolation and identification of these Nabs and their dominant target, α-1,3-galactose, led to a race to eliminate α-1,3-galactosyltransferase (Gal) from pig genomes. Once these genetically modified GalTKO pigs were available in 2003, the senior author of this review performed the first life-supporting GalTKO pig-to-baboon kidney transplant. Hyperacute rejection was successfully avoided in this case, and baboon survival was extended further – from 29 days with hCD55 grafts (43) to 83 days (44) – when combining these genetically modified kidneys with tolerance strategies (discussed later). Since this initial breakthrough, the scientific community has made remarkable recent strides in our ability to modify the pig genome to create organs suitable for transplant in humans.

**A. Early Application of Gene Editing Technologies in Xenotransplantation**

Before GalTKO pigs were available, researchers used various techniques to deplete preformed Nabs, including plasmapheresis, immunoadsorption columns, and use of a xenograft to act as a sponge (i.e. transplanting one kidney to absorb antibodies, and then removing it and replacing it with a second kidney) (45). These methods achieved some success, especially when used in combination with the first transgenic pigs, which were created using recombinant DNA plasmid embryo microinjection and
expressed human complement regulatory proteins CD59 (Fodor, PNAS, 1994) and then CD55 (33, 46). However, Nabs returned after initial depletion and prevented long-term graft survival.

In 2002 and 2003, two groups created the first GalTKO pigs using somatic cell nuclear transfer technology, and provided a major breakthrough in the field of pig-to-primate transplantation (25–27, 47). Subsequent preclinical studies demonstrated that transplantation of heart or kidney xenografts using GalTKO pigs were significantly less likely to undergo hyperacute rejection (44, 48). Instead, these grafts – with the exception of those that were co-transplanted with thymus tissue – were rejected after weeks to months, and rejection was correlated with elicited anti-non gal antibodies.

B. CRISPR-Cas9 and Current Targets of Gene Modification

Because xenografts using GalTKO pigs were still ultimately rejected, researchers sought to eliminate newly revealed targets of anti-non-gal Nabs, and to further modify these knockout animals with additional human transgenes. This process was slow, and multiply modified pigs proved difficult to produce. However, discovery of CRISPR-Cas9 facilitated rapid genome manipulation and led to creation of animals – as were used by UMMC and UAB – with ten genetic modifications (16).

The first category genetic manipulation involves removal of genes to eliminate targets of Nabs. In addition to α-1,3-galactose (carbohydrate produced by α-1,3-galactosyltransferase), two other Nabs targets were discovered, including Neu5Gc (produced by cytidine-monophosphate-N-acetyl-neuraminic acid hydroxylase, or CMAH, inactivated in humans), and SDa (produced by beta-1,4-galactosyltransferase), two other Nabs targets were discovered, including Neu5Gc (produced by CMAH knockout. Old world primates have a functional CMAH gene and so do not have Nabs that bind to anti-Neu5Gc; paradoxically, inactivation of CMAH gene increased NHP antibody binding when compared to GalTKO alone, which suggests that inactivation of CMAH may reveal new epitopes and present new targets for Nabs. (52).

The second major category of genetic modification involves insertion of human transgenes to correct for dysregulation in complement, coagulation, and inflammatory pathways due to species incompatibilities. As mentioned above, the first genetically modified pigs created for xenotransplantation included human complement regulatory proteins CD55 (33, 46) and later iterations included CD46 (53). Coagulation regulatory proteins including human thrombomodulin (hTBM) and endothelial protein receptor C (EPCR) were also early targets of genetic modification (54). More recent targets include anti-inflammatory proteins like heme-oxygenase (HO-1) (55, 56) and anti-phagocytic proteins, including human macrophage inhibitory ligand CD47 (57). With the advent of CRISPR-Cas9 gene editing technologies, it is now possible to combine these genetic manipulations and create multiply modified animals.

C. Limits of Gene Modification for Xenotransplantation

This extraordinary progress has led some to speculate that xenotransplantation will ultimately be accomplished through ever increasing genetic modification. This may be part of the answer, but there are three key issues with this approach. First, the xenotransplant community remains divided over exactly which genetic modifications are necessary. While some modifications, including GalTKO, are well-studied, others are supported only by mouse models or by a small number of cases in NHP models. Cost is a major obstacle to definitive research here, as genetically modified animals are expensive to produce, and transplants in NHPs are expensive to conduct. However, these modifications may have unintended consequences (e.g., creation of neoepitopes, seen in transplant of CMAH KO pigs to old world monkeys) (58), and it is important that each individual modification is subject to rigorous scrutiny.

Second, while genes may be reliably incorporated within the genome using new gene editing technologies, uneven gene expression in transgenic animals remains an issue. Of particular concern is tissue-specific gene expression. For example, transgenes that are only expressed in the liver will not be effective in kidney xenotransplantation. On a more granular level, studies have shown that human CD47 expression in pig endothelial cells and podocytes prevented phagocytosis by correcting CD47-SIRPα species incompatibilities and enabling normal SIRPα signal transduction. Indeed, hCD47 expression on podocytes in hCD47/GalTKO pig-to-baboon kidney transplants was shown to inhibit the development of proteinuria (59). However, our data also demonstrated that high hCD47 expression in renal tubular cells may lead to destructive inflammatory responses via the hCD47-TSP-1 pathway (59). More research is needed to further refine and reliably predict gene expression in multiply modified pigs.

Third, while genetic modifications may help protect pig xenografts from innate responses, genetic engineering alone is not sufficient to prevent rejection long-term, given the overwhelming number of possible xenantigens that could trigger adaptive responses and antibody-mediated rejection. Accordingly, additional strategies such as targeted immunosuppression or, as will be discussed in the following section, tolerance induction of B and T cells, will be required for long-term survival or xenografts.

STRATEGIES TO PROMOTE TOLERANCE IN PIG-TO-HUMAN TRANSPLANTATION

Tolerance-inducing approaches have achieved donor-specific tolerance of renal grafts in allotransplantation and have been under investigation for use in xenotransplantation for over twenty-five years. One of the first hurdles in applying this strategy in pig-to-human transplantation was theoretical: MHC interactions and costimulatory signaling are essential for the
development of tolerance, and there was concern that these interactions would be limited by species incompatibilities (37). However, subsequent studies demonstrated effective interspecies adaptive immune interactions and dispelled initial skepticism about the ability of human and pig T cells to communicate effectively (39, 60). Eventually, tolerance induction may allow for reduction or cessation of immunosuppression; in the near-term, these tolerance strategies may serve as a critical adjunct to immunosuppression to overcome xenogeneic barriers. The specific strategies addressed by this review include 1) thymic transplantation and 2) mixed hematopoietic cell chimerism.

A. Vascularized Thymic Transplantation

Transplantation of donor thymus has proven to be a potent strategy for tolerance induction. While this method is less studied in clinical allotransplantation than mixed hematopoietic chimerism, thymic transplantation has emerged as most effective tolerance strategy for xenotransplantation currently under investigation.

Early studies from Sykes et al. demonstrated that transplantation of porcine thymic tissue in thymectomized mice resulted in production of mature mouse T cells that were tolerant of porcine thymic tissue in thymectomized mice resulted in intrathymic deletion of donor reactive T cells (61, 62). These studies helped to resolve concerns about the efficacy of MHC interactions across xenogeneic barriers and paved the way for subsequent large animal studies. However, non-vascularized pig thymic grafts did not survive long enough to engraft or to promote tolerance in early large animal studies – grafts were rejected and recipient pigs found to have anti-donor elicited antibodies even across allogeneic barriers in a pig-to-pig model (63).

To prevent rejection of these ischemic thymic grafts, the senior author of this review developed two methods to transplant vascularized thymic grafts: (1) composite thymus+kidney (“thymokidney”) transplant (Figures 1A, B) (64); and (2) vascularized thymic lobe transplant (Figure 1C) (65) in the late 1990s and early 2000s. These vascularized thymic grafts proved able to participate immediately in the induction of tolerance and supported thymopoiesis across allogeneic swine kidney and heart transplant models (66–70). While these gains in pig-to-primate transplantation were modest in the era before GalTKO pigs, likely due to robust Nab binding, the results were striking when using organs from the first GalTKO pig: thymus co-transplantation with GalTKO kidneys prolonged survival of recipient baboons from 29 days (43) to 83 days with donor-specific unresponsiveness (44). While this strategy successfully prevented sensitization of recipient baboons to the xenograft, all baboon recipients suffered serious complication of nephrotic proteinuria. Despite relatively preserved renal function and renal histology showing only minimal absence of anti-pig antibody (Ab) deposits by immunofluorescence, proteinuria was observed as early as post-operative day (POD) 2 (71). Over the past 5 years, we have developed strategies to prevent proteinuria, combining novel therapeutic agents (including CTLA4-Ig) with additional genetic engineering (hCD47) (18, 71, 72). With these new regimens, we achieved long-term survival of >6 months in multiple recipients of vascularized thymus plus kidneys (18, 59). While hCD47 may be helpful, it is worth noting that we were able to avoid early development of proteinuria and achieve 193 days of rejection free survival using kidney+thymus from GalTKO pig without further genetic modification (18). Given uncertainty about which genetic modifications are necessary and the unintended consequences of additional modifications, “single-gene” kidneys (GalTKO alone) – combined with our vascularized thymic graft to induce tolerance – may represent the best path forward in recipients with low levels of anti-pig non Gal preformed NAb. The NYU group elected to use thymokidneys in their pig-to-human kidney transplants in brain dead patients, September–November, 2021 (NYTimes, Oct 21st, 2021).

Both types of vascularized thymic grafts appear to be effective at inducing tolerance of co-transplanted donor kidneys across xenogeneic barriers (18, 44, 59), but there are advantages and disadvantages to each method. Thymokidneys (64) may be more feasible to create and thus more broadly applicable for kidney xenotransplantation; vascularized thymic lobe (VTL) (65) harvest is technically challenging and prone to ischemia due to convoluted blood supply. However, in contrast to the thymokidney, VTL may theoretically be used to induce tolerance of any other organ graft (70). Additional studies will compare these methods of thymic graft creation, will combine thymic transplantation with mixed chimerism tolerance strategies, and will explore the role of thymus co-transplantation in tolerance induction of other solid organs.

B. Mixed Hematopoietic Cell Chimerism

Mixed bone marrow chimerism – in which a recipient produces both donor and recipient (self) hematopoietic cells through hematopoietic stem cell transplantation (HSCTx) after non-myeloablative conditioning (73–75) – has been shown to induce tolerance across HLA barriers in multiple clinical studies (76–78). Early studies in pig-to-mouse transplant models suggested that mixed chimerism was possible with non-myeloablative conditioning regimens (79), and that this strategy could induce tolerance across xenogeneic barriers in a rodent model. Critically, mixed chimerism in mice was found to induce tolerance to the α-gal epitope, demonstrating tolerance of B cells with disappearance of natural antibodies (80). Thus, not only did mixed chimerism prevent hyperacute rejection in rodent models, but it also prevented T-cell mediated rejection and antibody-mediated rejection (81) in a pig-to-mouse model.

However, mixed chimerism has proven more difficult to achieve in preclinical pig-to-primate transplant models. Attempts of GalTKO pig HSCTx in baboons resulted in loss of bone marrow cells within 24 to 48 hours (82, 83). This rapid elimination of xenogeneic cells is likely due to innate immune mechanisms: primate macrophages have been shown to phagocytose porcine cells independent of antibody or complement binding (84) and may be related to species incompatibilities between porcine macrophage inhibitory ligand CD47 and human macrophage SIRPα which result in failure of anti-phagocytosis signaling (85). As mentioned earlier, one strategy to prevent this problem of early phagocytosis is to create transgenic pigs expressing hCD47. In a pig-to-baboon skin transplant model, hematopoietic cells from transgenic pigs expressing hCD47 lasted longer than cells from pigs with porcine CD47 after HSCTx; accordingly, skin grafts from hCD47 pigs demonstrated improved survival when compared to grafts from
CD47 wild type pigs (86). In this way, genetic engineering may be used to facilitate tolerance strategies by allowing for the establishment of mixed chimerism.

Another strategy to avoid rapid consumption of porcine hematopoietic stem cells after HSCTx and promote bone marrow engraftment is to inject porcine bone marrow cells directly into the bone. The senior author of this review developed the intra-bone bone marrow (IBBM) transplant procedure in a pig-to-baboon model. This technique prolonged peripheral macrochimerism for 3 weeks and enabled engraftment of porcine hematopoietic progenitors in four of six baboon recipients of GalTKO pigs (87). Moreover, enhanced mixed chimerism after IBBM Tx resulted in transient anti-pig unresponsiveness that translated to prolonged survival of GalTKO kidneys after subsequent kidney transplant. Notably, by combining these methods, using hCD47-GalTKO pigs and IBBM Tx, we have achieved >60 days macrochimerism associated with reduction in anti-pig IgG (88). Despite initial setbacks, mixed chimerism remains a promising approach for induction of tolerance across xenogeneic barriers.

Although vascularized thymic transplant can induce T cell tolerance and inhibit T cell-mediated B cell and NK cell responses across xenogeneic barriers, B cells and NK cells are not “tolerized” by thymic transplantation in a pig-to-baboon model. Additional gene knockouts may limit rejection of pig organs by non-Gal Nabs, but run the risk of exposing new, currently unidentified, antigenic targets and/or compromising the health of the pig. Accordingly, we are currently working on combining vascularized thymus and IBBM Tx strategies to establish robust long-term T and B cell tolerance in xenotransplantation.

**CONCLUSION**

Once a researcher’s pipe dream, xenotransplantation is now becoming a clinical reality. After many years of progress, catalyzed by advances in gene editing technologies, three groups have confirmed decades of NHP research and established the short-term viability of pig-to-human transplantation. All three pig-to-human experiments demonstrated that hyperacute rejection (NYU, UAB, and UMMC) can be avoided through use of genetically modified pigs and immunosuppression. UMMC’s pig-to-human heart transplant represents a landmark accomplishment and the start of a new era in clinical xenotransplantation. Despite the success of this critical initial step, the UMMC patient’s clinical course should also serve to galvanize the application of innovative
strategies, such as tolerance induction, to ensure long-term survival of pig xenografts.

**AUTHOR CONTRIBUTIONS**

DE: Primarily in writing the review paper. YH: Participated in data analysis of the cited references. KY: Corresponding author. Primarily outlines and finalizes the review paper. All authors contributed to the article and approved the submitted version.

**FUNDING**

This research was partially supported by NIH grant, P01AI45897 and U01 AI152881.
